AN2 Therapeutics
potential to reduce mortality in patients soc alone | AN2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
March 2025
Slide
20 of 36
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
February 2025
potential to reduce mortality in patients soc alone | AN2 Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
August 2022
potential market opportunity in | BioAtla
BenevolentAI
Investor Presentation
October 2022
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Dynacure
IPO
July 2021
patient pool us japan with a significant market potential | Dynacure
Aeglea BioTherapeutics
Investor Presentation
August 2020
increased mortality and severe complication risk in patients with | Aeglea BioTherapeutics
Other recent decks by AN2 Therapeutics
See all presentations (4 decks)
Investor Presentation
February 2025
Investor Presentation
August 2022
IPO
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io